Damon DeSantis Group Consolidates 41.3% Controlling Stake in Integrated BioPharma
INBP sits 30% above its 52-week low of $0.216.
Summary
Damon DeSantis and his controlled entity, CDDS 2.0, LLC, have filed a Schedule 13D, reporting beneficial ownership of 41.3% of Integrated BioPharma's common stock through a series of non-cash transfers.
Key Events · Ownership and Investor Activity · INBP
-
Controlling Stake Established
Damon DeSantis and CDDS 2.0, LLC collectively report beneficial ownership of 12,920,558 shares, representing 41.3% of the company's outstanding common stock.
-
Non-Cash Transfers
The shares were acquired through a series of transfers from CD Financial, LLC, the Carl DeSantis Revocable Trust, and the Estate of Carl DeSantis, with no cash consideration.
-
No Immediate Strategic Plans
The filing states that the reporting persons have no present intentions or plans for major corporate actions, but reserve the right to change their intentions.
Analysis · INBP · Life Sciences
This Schedule 13D filing reveals a significant consolidation of ownership, with Damon DeSantis and his entity, CDDS 2.0, LLC, now beneficially owning 41.3% of Integrated BioPharma. While the shares were acquired through non-cash transfers from related family trusts and entities, this establishes a controlling stake for the DeSantis group. This level of ownership grants substantial influence over corporate decisions and could impact future strategic directions, even though the filing states no present plans for major corporate changes. Investors should monitor any future amendments to this Schedule 13D for changes in stated intentions or further transactions.
At the time of this filing, INBP was trading at $0.28 on OTC in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.22 to $0.42. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.